Analysis Of Income And Expense [Abstract]

Ascelia Pharma - Filing #678716

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	- SEK	—	—	—	—	—	—	- SEK	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	81 266 SEK	—	—	—	—	—	—	118 113 SEK	—	—	—	—
Finance income (cost)	—	—	1 307 SEK	—	—	—	—	—	—	13 851 SEK	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	- SEK	- SEK	301,000 SEK	- SEK	- SEK	301,000 SEK	301,000 SEK	- SEK	718,000 SEK	718,000 SEK	- SEK	- SEK	718,000 SEK	- SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- SEK	- SEK	109 589 SEK	- SEK	109 288 SEK	109 589 SEK	301,000 SEK	- SEK	130 504 SEK	130 504 SEK	131 223 SEK	- SEK	718,000 SEK	- SEK